Literature DB >> 18165649

Brain metastases in patients with renal cell cancer receiving new targeted treatment.

Helgi H Helgason1, Henk A Mallo, Helga Droogendijk, John G Haanen, Astrid A M van der Veldt, Alfonsus J van den Eertwegh, Epie Boven.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18165649     DOI： 10.1200/JCO.2007.13.5814

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  18 in total

1.  Which patients with renal cancer may benefit from sunitinib therapy?

Authors:  Tom Ferguson; Martin Gore
Journal:  Ther Adv Med Oncol       Date:  2010-03       Impact factor: 8.168

Review 2.  Targeted therapies in renal cell cancer: recent developments in imaging.

Authors:  Astrid A M van der Veldt; Martijn R Meijerink; Alfons J M van den Eertwegh; Epie Boven
Journal:  Target Oncol       Date:  2010-07-14       Impact factor: 4.493

3.  Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma.

Authors:  Jonathan Verma; Eric Jonasch; Pamela Allen; Nizar Tannir; Anita Mahajan
Journal:  Cancer       Date:  2011-04-11       Impact factor: 6.860

4.  The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinoma.

Authors:  Jonathan Verma; Eric Jonasch; Pamela K Allen; Jeffrey S Weinberg; Nizar Tannir; Eric L Chang; Anita Mahajan
Journal:  Am J Clin Oncol       Date:  2013-12       Impact factor: 2.339

5.  Progression of intramedullary metastasis during perioperative cessation of sunitinib.

Authors:  Fausto Petrelli; Mary Cabiddu; Marinella Carpo; Mara Ghilardi; Sandro Barni
Journal:  Nat Rev Urol       Date:  2010-10-12       Impact factor: 14.432

6.  Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.

Authors:  A A M van der Veldt; M R Meijerink; A J M van den Eertwegh; J B A G Haanen; E Boven
Journal:  Br J Cancer       Date:  2010-02-09       Impact factor: 7.640

7.  Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer.

Authors:  Rebecca A Miksad; Kuan-Chi Lai; Marion C Stein; Megan E Healy; Rafael Rojas; Katherine M Krajewski; Andrew X Zhu
Journal:  J Gastrointest Cancer       Date:  2009

8.  Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model.

Authors:  Qingyu Zhou; James M Gallo
Journal:  Neuro Oncol       Date:  2008-10-29       Impact factor: 12.300

Review 9.  Oral Targeted Therapies and Central Nervous System (CNS) Metastases.

Authors:  Michael P Gabay; Scott M Wirth; Joan M Stachnik; Colleen L Overley; Katie E Long; Linda R Bressler; John L Villano
Journal:  CNS Drugs       Date:  2015-11       Impact factor: 5.749

Review 10.  Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations.

Authors:  Javier Puente; Xavier García Del Muro; Álvaro Pinto; Nuria Láinez; Emilio Esteban; José Ángel Arranz; Enrique Gallardo; María José Méndez; Pablo Maroto; Enrique Grande; Cristina Suárez
Journal:  Target Oncol       Date:  2016-04       Impact factor: 4.493
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.